Drug Search Results
More Filters [+]

Sarpogrelate

Alternative Names: sarpogrelate, mci-9042, anplag
Latest Update: 2024-07-02
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: 5-HT2A Antagonist,GPIIb/IIIa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Korea

Approved Indications: None

Known Adverse Events: None

Company: Daewoong
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Sarpogrelate

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Kidney Diseases|Angina Pectoris, Variant|Coronary Artery Disease|Myocardial Ischemia|Diabetic Nephropathy|Peripheral Arterial Disease|Peripheral Vascular Diseases|Thrombophilia|Intermittent Claudication|Arterial Occlusive Diseases|Kidney Failure, Chronic

Phase 3: Ischemic Stroke|Kidney Failure, Chronic|Coronary Artery Disease|Peripheral Vascular Diseases|Peripheral Arterial Disease|Myocardial Ischemia

Phase 1: Healthy Volunteers|Chronic Pain|Peripheral Arterial Disease|Hypertension|Malnutrition

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

SEUMC 2023-10-009

N/A

Not yet recruiting

Atherosclerosis|Intermittent Claudication|Stroke

2028-06-30

YMC047

P4

Recruiting

Coronary Artery Disease|Myocardial Ischemia|Peripheral Arterial Disease|Peripheral Vascular Diseases

2024-02-28

YMC044

P4

Completed

Arterial Occlusive Diseases|Intermittent Claudication

2023-03-09

DWAP_P401

N/A

Completed

Arterial Occlusive Diseases

2022-01-20

Recent News Events